nabe

L-Nabe (H-Arg(NO2)-Obzl) is a effective irreversible endothelium dependent relaxation inhibitor.

Prinaberel (ERB 041) is a selective and potent estrogen receptor β (ERβ) agonist with anticancer activity that restores or increases ERβ expression and reduces cancer cell proliferation in mouse squamous cell carcinoma and human carcinoma cells. Prinaberel exhibits anti-inflammatory activity, inhibits the NFκB pro-inflammatory signaling pathway, and induces apoptosis of ovarian cancer cells. study endometriosis.

Guanabenz Acetate (Wytensin) is a specific agonist of adrenergic receptor. The pEC50 for α2a-adrenergic receptor, α2b-adrenergic receptor and α2c-adrenergic receptor is 8.25, 7.01 and ~5, respectively.

(1α,1'S,4β)-Lanabecestat is a Beta site APP Cleaving Enzyme 1 (BACE1) inhibitor with IC50 values of 2.2 nM in the TR-FRET assay and 0.28 nM in the sAPPp release assay.

Tonabersat (SB-220453) is a novel and orally available gap-junction modulator and CSD (Cortical spreading depression) inhibitor that regulates cellular communication between trigeminal ganglion neuronal cells and glial cells and inhibits neurogenic inflammation for the treatment of migraine and epilepsy.

Chloroguanabenz (acetate) is an antiprion agent derived from guanabenz, an α2-adrenergic receptor agonist. It inhibits prion formation in vitro in both yeast and mammalian models. Additionally, Chloroguanabenz (acetate) reduces levels of the truncated huntingtin protein derivative Htt48 in HEK293T cells and is used for studying Huntington's disease.

Guanabenz hydrochloride (NE56490) is an orally active α2-adrenoceptor agonist with hypotensive effects.

Lanabecestat camsylate is used as a BACE1 Inhibitor.

Chloroguanabenz is an antiprion agent and a derivative of the α2-adrenergic receptor agonist guanabenz . It inhibits prion formation in yeast and mammalian cell-based assays. Chloroguanabenz reduces the levels of both soluble and aggregated forms of the truncated Huntingtin derivative Htt48 in an HEK293T cellular model of Huntington's disease.

GUANABENZ is a Central alpha-2 Adrenergic Agonist. The mechanism of action of guanabenz is as an Adrenergic alpha2-Agonist.

(E)-Guanabenz ((E)-Wy-8678), an oral central α2-adrenoceptor agonist, exhibits antihypertensive and neuroprotective activities by stimulating central α2-adrenoceptors to reduce sympathetic outflow and directly inhibiting GADD34. It is used in researching hypertension and Parkinson's disease [1] [2].

Lanabecestat, also known as AZD3293 and LY3314814, is a potent, highly permeable, orally active, blood-brain barrier (BBB) penetrating, BACE1 inhibitor with unique slow off-rate kinetics. AZD3293 displayed significant dose- and time-dependent reductions in plasma, cerebrospinal fluid, and brain concentrations of Aβ40, Aβ42, and sAβPPβ.

Inabenfide (Standard) is a reference standard of Inabenfide intended for quantitative analysis, quality control, and related biochemical research applications.

Prostephanaberrine is a natural product from Stephania japonica.

Lanabecestat (AZD3293) is a highly potent and highly permeable, orally active BACE1 inhibitor (Ki: 0.4 nM) that crosses the blood-brain barrier, Lanabecestat can be used for the study of neurological diseases like Alzheimer's disease.

Guanoxabenz, an α2 adrenergic receptor agonist, exhibits properties that make it significant in biochemical research and potential therapeutic applications.

GZD856 is an orally bioavailable inhibitor of PDGFRα and PDGFRβ with IC50 values of 68.6 and 136.6 nM, respectively. GZD856 has demonstrated anti-lung cancer activities in experimental studies. The molecular activity profile of GZD856 supports its utilization in research investigating PDGFR-associated signaling pathways, tumor biology, kinase inhibition, and mechanisms relevant to lung cancer progression.

Nadolol is a non-selective beta-adrenergic antagonist with antihypertensive and antiarrhythmic activities. Nadolol competitively blocks beta-1 adrenergic receptors located in the heart and vascular smooth muscle, inhibiting the activities of the catechola

Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).

Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).

Diethylnorspermine, also known as DENSPM, BE-333, DE-333 and N(1),N(11)-Diethylnorspermine, is a highly potent known inducer of the polyamine catabolic enzyme, spermidine/spermine N1-acetyltransferase (SSAT). A designed polyamines (PAs) analog which induces cell cycle arrest, inhibits proliferation and induces apoptosis in melanoma, breast, prostate, lung and colon cancer cells..